Archived Content

Track 7: Exosomes and Microvesicles
as Biomarkers and Diagnostics
 


Day 1 | Day 2 | Download Brochure 


Tuesday, May 7


12:15-1:45 Conference Registration


Exosome Biomarkers in Drug Development 

1:45-1:50 Chairperson’s Opening Remarks

1:50-2:15 Exosomes as Biomarkers for Translational Medicine

Holly Hilton, Ph.D., Adjunct Professor, Graduate School of Biomedical Sciences, University of Medicine and Dentistry New Jersey

The need for new, relevant biomarkers for translational drug discovery research is critical. Exosomes are small microvesicles secreted by a wide range of mammalian cell types under normal and pathological conditions. The unique signature of exosomal membrane and cytoplasmic proteins as well as mRNAs and miRNAs can reveal the cell of origin and the condition of those cells. Isolation and profiling of exosomes from accessible patient biofluids, such as urine, blood, BALF and CSF, make them ideal candidates as biomarkers. Examples of their utility as disease biomarkers of chronic kidney disease and Alzheimer’s as well as possible applications of patient stratification will be discussed. The current state of challenges to the widespread use of fluid-based biomarkers will be explored.

2:15-2:40 Investigation of Microparticles as Potential Translatable Biomarkers of Vascular Injury

Sharon Sokolowski, Ph.D., Principal Scientist, Pfizer Global Research & Development

Endothelial cells (EC) are thin, flattened cells that line blood and lymph vessel walls. Endothelial microparticles (EMPs) are small vesicles (0.1-1 mm) that are released into circulating blood from activated, injured or apoptotic endothelial cells and are found at elevated levels in a number of diseases associated with vascular/endothelial dysfunction. The EMPs are being investigated as potential translatable biomarkers of drug-induced vascular injury.

2:40-3:45 Refreshment Break in the Exhibit Hall with Poster Viewing

3:45-4:10 Utilization of Next-Gen Genomics Technologies for Unraveling Exosomal Biomarker Potential

Saumya Pant, Ph.D., Research Fellow, Merck

4:10-4:35 Technology Assessment for Evaluation of Exosomal microRNA as Novel Biomarkers

Shidong Jia, Ph.D., Scientist, Oncology Biomarker Development, Genentech

Dr. Jia’s lab has developed working procedures to evaluate exosomal microRNA as novel biomarkers for cancer prognosis, prediction and patient stratification. In particular, their work has refreshed current practice and demonstrated a new approach for studying microRNA signature in patient blood samples.

6:00-9:00 Dinner Course

Laboratory-Developed Tests

(Separate registration required)



Day 1 | Day 2 | Download Brochure